Analysts Set Zoetis Inc. (NYSE:ZTS) PT at $215.90

Shares of Zoetis Inc. (NYSE:ZTS) have received an average rating of “Buy” from the twelve research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $215.90.

A number of research firms have weighed in on ZTS. UBS Group started coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Piper Sandler raised their target price on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Barclays lifted their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th.

Zoetis Stock Performance

ZTS stock opened at $151.76 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market cap of $67.96 billion, a PE ratio of 27.74, a P/E/G ratio of 2.78 and a beta of 0.92. The business has a 50 day moving average of $165.71 and a 200-day moving average of $173.43. Zoetis has a 12-month low of $144.80 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, sell-side analysts expect that Zoetis will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.32%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Insider Activity

In other news, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock worth $312,254 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Moody National Bank Trust Division boosted its holdings in shares of Zoetis by 1.4% in the 1st quarter. Moody National Bank Trust Division now owns 9,319 shares of the company’s stock worth $1,534,000 after purchasing an additional 133 shares in the last quarter. Versant Capital Management Inc lifted its position in Zoetis by 177.8% in the 1st quarter. Versant Capital Management Inc now owns 3,095 shares of the company’s stock worth $510,000 after buying an additional 1,981 shares during the last quarter. First Hawaiian Bank boosted its stake in Zoetis by 14.0% in the first quarter. First Hawaiian Bank now owns 3,085 shares of the company’s stock worth $508,000 after buying an additional 379 shares in the last quarter. Jacobs & Co. CA grew its position in Zoetis by 1.2% during the first quarter. Jacobs & Co. CA now owns 96,591 shares of the company’s stock valued at $15,903,000 after acquiring an additional 1,150 shares during the last quarter. Finally, Park National Corp OH raised its stake in shares of Zoetis by 0.5% during the first quarter. Park National Corp OH now owns 86,562 shares of the company’s stock worth $14,252,000 after acquiring an additional 426 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.